

a 2013 0005

The invention relates to pharmaceuticals, namely to minigranules for sustained release of trimetazidine, wherein an inner phase comprises trimetazidine dihydrochloride deposited on a neutral core and a binder, and an outer layer comprises a retardant, an anti-agglomerant and a plasticiser.

The minigranules, according to the present invention, provides a gradual and sustained release of trimetazidine over 24 hours at a therapeutic efficacious plasma concentration and an availability of trimetazidine at a therapeutic efficacious plasma concentration following the administration.

The invention also describes a process for manufacture of minigranules and use thereof in the prophylactic treatment of angina pectoris, in the course of chorioretinal disorders and also in the treatment of vertigo of vascular origin.

Claims: 11

Fig.: 5